Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CDC14B | O60729 | 1/20 | 0.45 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9796733 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL29685650 | 0.83 | ALDH1A1 (0.54) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL516363 | 0.83 | ALDH1A1 (0.54) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL30476189 | 0.81 | ALDH1A1 (0.76) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL2012858 | 0.81 | ALDH1A1 (0.76) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL11401526 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL6238717 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL4586057 | 0.80 | ALOX5 (0.48) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| Silver SCHEMBL11471729 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GLAMAOAKDM4ECYP3A4 | |
| SCHEMBL22645255 | 0.79 | MAPT (0.53) | ALDH1A1GLAMAOAMAPTCDC14B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CYTOVIA INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| EP-1804786-A4 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1804786-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006039356-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CASP1, CASP9, CASP14 | ALDH1A1 1418/4885GLA 3006/4885MAOA 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.